In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells

  • Authors:
    • Uriel Francisco Santana‑Bejarano
    • Lucina Bobadilla‑Morales
    • Lucero Mendoza‑Maldonado
    • Elizabeth Torres‑Anguiano
    • Sinhue Alejandro Brukman‑Jiménez
    • Cesar Cenobio Barba‑Barba
    • Jorge Román Corona‑Rivera
    • Alfredo Corona‑Rivera
  • View Affiliations

  • Published online on: April 2, 2019     https://doi.org/10.3892/ol.2019.10204
  • Pages: 5224-5240
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL), is characterized by the t(9;22)(q34q11) that generates the BCR‑ABL protein with uncontrolled tyrosine kinase activity. Recently, a connection between BCR‑ABL signaling with NF‑κB activation mediated by CK2 has been hypothesized. Approximately 95% of patients with Ph+ ALL have the BCR‑ABLp190 isoform, which causes aggressive leukemia with a high rate of chemotherapy resistance. Therefore, the use of compounds that could improve the efficacy of chemotherapy drugs is of particular interest. Curcumin is an active chemical in turmeric with antineoplastic potential; it regulates protein‑kinases by modulating downstream molecular pathways. The present study evaluated the effect of curcumin in combination with the chemotherapeutic drugs vincristine, imatinib and daunorubicin in the human OP‑1 cell line. Several doses of the chemotherapy drugs were examined, and the effects were evaluated following 12, 24 and 48 h of exposure. The interaction between the chemotherapy drugs and curcumin was determined by the dose‑effect curve, which generated a combination index (CI); these data were represented in isobolograms. In addition, the individual effect of each drug was compared with its effect in combination with curcumin on cell viability, apoptosis degree, NF‑κB activation and gene expression changes. The present study observed that curcumin potentiates the efficacy of vincristine and imatinib, generating an additive/synergistic effect in a dose‑ and time‑dependent manner. These combinations significantly increased the apoptosis degree, decreased the activation of NF‑κB and the expression of its regulated genes. Conversely treatment with daunorubicin + curcumin combination produced an antagonistic/additive effect in a dose‑dependent manner, and this combination significantly increased the apoptosis degree. However, this effect seems not to be associated with NF‑κB activity, as no significant changes were observed in its activation or in the expression of the genes that it regulates. The results of the present study demonstrate that curcumin may be used as an adjuvant agent for chemotherapy in patients with Ph+ ALL.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Santana‑Bejarano, U.F., Bobadilla‑Morales, L., Mendoza‑Maldonado, L., Torres‑Anguiano, E., Brukman‑Jiménez, S.A., Barba‑Barba, C.C. ... Corona‑Rivera, A. (2019). In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells. Oncology Letters, 17, 5224-5240. https://doi.org/10.3892/ol.2019.10204
MLA
Santana‑Bejarano, U. F., Bobadilla‑Morales, L., Mendoza‑Maldonado, L., Torres‑Anguiano, E., Brukman‑Jiménez, S. A., Barba‑Barba, C. C., Corona‑Rivera, J. R., Corona‑Rivera, A."In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells". Oncology Letters 17.6 (2019): 5224-5240.
Chicago
Santana‑Bejarano, U. F., Bobadilla‑Morales, L., Mendoza‑Maldonado, L., Torres‑Anguiano, E., Brukman‑Jiménez, S. A., Barba‑Barba, C. C., Corona‑Rivera, J. R., Corona‑Rivera, A."In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells". Oncology Letters 17, no. 6 (2019): 5224-5240. https://doi.org/10.3892/ol.2019.10204